title: Site specific effects of zoledronic acid during tibial and mandibular fracture repair.
abstract: Numerous factors can affect skeletal regeneration, including the extent of bone injury, mechanical loading, inflammation and exogenous molecules. Bisphosphonates are anticatabolic agents that have been widely used to treat a variety of metabolic bone diseases. Zoledronate (ZA), a nitrogen-containing bisphosphonate (N-BP), is the most potent bisphosphonate among the clinically approved bisphosphonates. Cases of bisphosphonate-induced osteonecrosis of the jaw have been reported in patients receiving long term N-BP treatment. Yet, osteonecrosis does not occur in long bones. The aim of this study was to compare the effects of zoledronate on long bone and cranial bone regeneration using a previously established model of non-stabilized tibial fractures and a new model of mandibular fracture repair. Contrary to tibial fractures, which heal mainly through endochondral ossification, mandibular fractures healed via endochondral and intramembranous ossification with a lesser degree of endochondral ossification compared to tibial fractures. In the tibia, ZA reduced callus and cartilage formation during the early stages of repair. In parallel, we found a delay in cartilage hypertrophy and a decrease in angiogenesis during the soft callus phase of repair. During later stages of repair, ZA delayed callus, cartilage and bone remodeling. In the mandible, ZA delayed callus, cartilage and bone remodeling in correlation with a decrease in osteoclast number during the soft and hard callus phases of repair. These results reveal a more profound impact of ZA on cartilage and bone remodeling in the mandible compared to the tibia. This may predispose mandible bone to adverse effects of ZA in disease conditions. These results also imply that therapeutic effects of ZA may need to be optimized using time and dose-specific treatments in cranial versus long bones.
authors.affiliation: Department of Orthopaedic Surgery, University of California San Francisco, San Francisco, California, United States of America.
authors.forename: Yan Yiu
authors.initials: YY
authors.lastname: Yu
authors.forename: Shirley
authors.initials: S
authors.lastname: Lieu
authors.forename: Diane
authors.initials: D
authors.lastname: Hu
authors.forename: Theodore
authors.initials: T
authors.lastname: Miclau
authors.forename: Céline
authors.initials: C
authors.lastname: Colnot
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling; D002356:Cartilage; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D017102:Fracture Healing / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008337:Mandibular Fractures / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D010020:Osteonecrosis; D012038:Regeneration / Q000187:drug effects; D013978:Tibial Fractures / Q000188:drug therapy*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid